Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008417/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a multicenter, randomized, double-blind, event-driven, superiority study for
efficacy.
Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who
completed 6 or 12 months of treatment of anticoagulation are eligible for this trial
提供机构：
Vivli
创建时间：
2022-09-02
